146 related articles for article (PubMed ID: 20429672)
1. Pharmacogenomics of pediatric acute lymphoblastic leukemia.
Meeker ND; Yang JJ; Schiffman JD
Expert Opin Pharmacother; 2010 Jul; 11(10):1621-32. PubMed ID: 20429672
[TBL] [Abstract][Full Text] [Related]
2. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.
Kager L
J BUON; 2009 Sep; 14 Suppl 1():S181-6. PubMed ID: 19785064
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.
Aplenc R; Lange B
Br J Haematol; 2004 May; 125(4):421-34. PubMed ID: 15142113
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
Ansari M; Krajinovic M
Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
[TBL] [Abstract][Full Text] [Related]
7. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations.
Al-Mahayri ZN; Patrinos GP; Ali BR
Pharmacogenomics; 2017 May; 18(7):687-699. PubMed ID: 28468529
[TBL] [Abstract][Full Text] [Related]
9. Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
Kaspers GJ; Zwaan CM
Haematologica; 2007 Nov; 92(11):1519-32. PubMed ID: 18024401
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of childhood acute lymphoblastic leukemia.
Brenner TL; Pui CH; Evan WE
Curr Opin Mol Ther; 2001 Dec; 3(6):567-78. PubMed ID: 11804271
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
Zuna J; Hrusák O; Kalinová M; Muzíková K; Zörnerová T; Starý J; Trka J
Vnitr Lek; 2000 Aug; 46(8):465-9. PubMed ID: 11048511
[TBL] [Abstract][Full Text] [Related]
12. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
Sims RP
J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.
Hartman A; van Schaik RH; van der Heiden IP; Broekhuis MJ; Meier M; den Boer ML; Pieters R
Leuk Res; 2010 Feb; 34(2):154-9. PubMed ID: 19467705
[TBL] [Abstract][Full Text] [Related]
15. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
16. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
17. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia.
Costea I; Moghrabi A; Laverdiere C; Graziani A; Krajinovic M
Haematologica; 2006 Aug; 91(8):1113-6. PubMed ID: 16870553
[TBL] [Abstract][Full Text] [Related]
18. Building better therapy for children with acute lymphoblastic leukemia.
Carroll WL; Raetz EA
Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
[TBL] [Abstract][Full Text] [Related]
19. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):351-63. PubMed ID: 11908928
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of acute lymphoblastic leukemia.
Kager L; Evans WE
Curr Opin Hematol; 2006 Jul; 13(4):260-5. PubMed ID: 16755223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
